Meyka Pro banner
HABA Laboratories,Inc.

HABA Laboratories,Inc. Fundamental Analysis (JPX: 4925.T)

4925.TJPX
Consumer DefensiveHousehold & Personal Products
¥1717.00
¥0.00(0.00%)
Japanese Market opens in NaNh NaNm

HABA Laboratories,Inc. Fundamental Analysis (JPX: 4925.T)

HABA Laboratories,Inc. (JPX: 4925.T) shows weak financial fundamentals with a PE ratio of 9.53, profit margin of 5.65%, and ROE of 7.37%. The company generates $12.0B in annual revenue with weak year-over-year growth of 0.66%.

Key Strengths

Cash Position79.31%
Current Ratio4.98

Areas of Concern

ROE7.37%
Operating Margin5.09%
We analyze 4925.T's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 41.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
41.2/100

We analyze 4925.T's fundamental strength across five key dimensions:

Efficiency Score

Weak

4925.T struggles to generate sufficient returns from assets.

ROA > 10%
5.84%

Valuation Score

Excellent

4925.T trades at attractive valuation levels.

PE < 25
9.53
PEG Ratio < 2
1.47

Growth Score

Moderate

4925.T shows steady but slowing expansion.

Revenue Growth > 5%
0.66%
EPS Growth > 10%
31.88%

Financial Health Score

Excellent

4925.T maintains a strong and stable balance sheet.

Debt/Equity < 1
0.10
Current Ratio > 1
4.98

Profitability Score

Weak

4925.T struggles to sustain strong margins.

ROE > 15%
7.37%
Net Margin ≥ 15%
5.65%
Positive Free Cash Flow
No

Key Financial Metrics

Is 4925.T Expensive or Cheap?

P/E Ratio

4925.T trades at 9.53 times earnings. This suggests potential undervaluation.

9.53

PEG Ratio

When adjusting for growth, 4925.T's PEG of 1.47 indicates fair valuation.

1.47

Price to Book

The market values HABA Laboratories,Inc. at 0.69 times its book value. This may indicate undervaluation.

0.69

EV/EBITDA

Enterprise value stands at 13.31 times EBITDA. This signals the market has high growth expectations.

13.31

How Well Does 4925.T Make Money?

Net Profit Margin

For every $100 in sales, HABA Laboratories,Inc. keeps $5.65 as profit after all expenses.

5.65%

Operating Margin

Core operations generate 5.09 in profit for every $100 in revenue, before interest and taxes.

5.09%

ROE

Management delivers $7.37 in profit for every $100 of shareholder equity.

7.37%

ROA

HABA Laboratories,Inc. generates $5.84 in profit for every $100 in assets, demonstrating efficient asset deployment.

5.84%

Following the Money - Real Cash Generation

Operating Cash Flow

HABA Laboratories,Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

HABA Laboratories,Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

4925.T converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

9.53

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.47

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.69

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.54

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.07

vs 25 benchmark

ROA

Return on assets percentage

0.06

vs 25 benchmark

ROCE

Return on capital employed

0.06

vs 25 benchmark

How 4925.T Stacks Against Its Sector Peers

Metric4925.T ValueSector AveragePerformance
P/E Ratio9.5321.73 Better (Cheaper)
ROE7.37%661.00% Weak
Net Margin5.65%-2335.00% (disorted) Weak
Debt/Equity0.100.81 Strong (Low Leverage)
Current Ratio4.982.28 Strong Liquidity
ROA5.84%313.00% Weak

4925.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews HABA Laboratories,Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-15.14%

Industry Style: Defensive, Dividend, Low Volatility

Declining

EPS CAGR

251.35%

Industry Style: Defensive, Dividend, Low Volatility

High Growth

FCF CAGR

131.38%

Industry Style: Defensive, Dividend, Low Volatility

High Growth

Fundamental Analysis FAQ